Vidaza is recommended for European licence
This article was originally published in Scrip
Celgene's Vidaza (5-azacitidine), a first-in-class DNA demethylating agent, has been given a positive opinion by the EU's CHMPfor the treatment of myelodysplastic syndromes and acute myeloid leukaemia in adults who are not eligible for haematopoietic stem-cell transplantation.
You may also be interested in...
Local health authorities in Coventry, UK, say it is most unlikely that vaccination with GlaxoSmithKline's Cervarix (human papillomavirus vaccine) was the cause of the death of a 14-year-old schoolgirl on September 28th.
Patents on Janssen-Cilag's (Johnson & Johnson) anti-epileptic Topamax/Epitomax (topiramate) expired in many European countries on September 25th, and generics companies are launching their own versions quickly.
Lilly's Alimta (pemetrexed) has been recommended as a first-line treatment for some patients in England and Wales with non-small cell lung cancer (NSCLC) in binding guidance for the national health service.